药物化学方法针对癌症中的MNK-eIF4E轴
Ann Fernandez1, Paige J Monsen1, Leonidas C Platanias2,3,4
1Department of Chemistry, Northwestern University Evanston IL 60208 USA gary-schiltz@northwestern.edu.
RSC medicinal chemistry
|June 26, 2023
概括
用小分子准MNK-eIF4E通路显示出癌症治疗的前景. 本综述涵盖了针对新癌症药物发现的这一轴的最新发展.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 异常的蛋白质翻译驱动癌症的进展.
- 细胞启动因子4E (eIF4E) 控制翻译启动.
- 在各种癌症中,MNK1/2-eIF4E轴经常失调.
研究的目的:
- 审查开发针对MNK-eIF4E途径的小分子治疗方法的最新进展.
- 探索各种分子策略,以准癌症治疗中的这一轴.
- 讨论指导这些药物的优化和测试的药物化学原理.
主要方法:
- 关于MNK-eIF4E抑制剂的最近研究的文献综述.
- 对针对MNK-eIF4E轴的不同组件的小分子抑制剂的分析.
- 对药物优化药物化学方法的讨论.
主要成果:
- 已经开发出几种针对MNK1/2激酶和eIF4E的小分子.
- 这些抑制剂在临床前癌症模型中显示出潜力.
- 药物化学的努力是优化功效,选择性和药用动力学特性.
结论:
- MNK-eIF4E轴代表了癌症的一个可行的治疗标.
- 针对这种途径的小分子抑制剂为新型癌症药物开发提供了有希望的途径.
- 药物化学的持续研究对于推动这些药物进入临床应用至关重要.
相关概念视频
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K


